Infliximab in Crohn's disease: First anniversary clinical experience

American Journal of Gastroenterology

Volumn 95, Issue 12, 2000, Pages 3469-3477

  Skacel, Marek ^a   Petras, Robert E ^a   Gramlich, Terry L ^a   Sigel, Jessica E ^a   Richter, Joel E ^a   Goldblum, John R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; PREDNISONE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0033634684     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02156-0     Document Type: Article

References (15)

1. Infliximab approved for use in Crohn's disease: A report on the FDA GI Advisory Committee conference
2. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
3. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease
4. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
5. Infliximab for the treatment of fistulas in patients with Crohn's disease
6. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
7. NJ, Physicians' Desk Reference Solumedrol
8. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
9. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
10. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis (see comments)
11. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis
12. Advances in the management of Crohn's disease: Economic and clinical potential of infliximab
13. Inflammatory bowel disease: Costs-ofillness
14. Inflammatory bowel disease: Medical cost algorithms
15. The cost of hospitalizations in Crohn's disease